




RealRate

PHARMACEUTICAL 2023

GYRE Therapeutics INC
Rank 289 of 471

CATALYST
BIOSCIENCES



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of GYRE Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GYRE Therapeutics INC compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 67% points. The greatest weakness of GYRE Therapeutics INC is the variable Liabilities, Current, reducing the Economic Capital Ratio by 126% points.

The company's Economic Capital Ratio, given in the ranking table, is 207%, being 37% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	28,206
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,824
Liabilities, Non-Current	0
Other Assets	234
Other Compr. Net Income	0
Other Expenses	-20,650
Other Liabilities	0
Other Net Income	717
Other Revenues	0
Property and Equipment	4.0
Research and Development	13,037
Selling, General and Administrative Expense	17,366

Output Variable	Value in 1000 USD
Assets	28,444
Liabilities	16,824
Expenses	9,753
Revenues	0
Stockholders Equity	11,620
Net Income	-9,036
Comprehensive Net Income	-9,036
BaseVar	27,869
ECR before Limited Liability	72%
Economic Capital Ratio	207%